Optimization of an allelic discrimination real‐time RT‐PCR assay for detection of H275Y oseltamivir resistance gene mutation among influenza A(H1N1)pdm09 patients from 2020 to 2022

Abstract

AbstractInfluenza virus is known to cause mild to severe respiratory infections and is also prone to genetic mutations. Of all the mutations, neuraminidase (NA) gene mutations are a matter of concern, as most approved antivirals target this protein. During the 2020 influenza season, an emergence of mutation in the NA gene, affecting the binding of the World Health Organization (WHO)‐recommended probes to the specific site of the NA gene, was reported by our group. As a result of this mutation, the WHO‐recommended allelic discrimination real‐time reverse transcriptase polymerase chain reaction (RT‐PCR) assay was unable to detect wild‐type (H275) or mutant oseltamivir‐resistant (Y275) strains of influenza A(H1N1)pmd09 viruses. In the current study, the WHO‐recommended probes were redesigned according to the mutation in the probe binding site. Fifty undetermined samples (2020–2021) from the previous study were retested with the newly designed probes and found to be positive for H275 and/or Y275. The results obtained were similar to the Sanger sequencing results from the previous study, suggesting that the redesigned probes were efficient in discriminating between wild‐type and mutant‐type viruses. Furthermore, 133 samples from 2022, making a total of 183 samples (2020–2022), were tested using improved allelic discrimination real‐time RT‐PCR, and the overall prevalence rate of oseltamivir resistance in 2020–2022 was found to be 0.54%.